Introduction::
Hepatic steatosis is a frequent condition, that afflicts, especially, obese and insulin resistant
patients; diagnosis is made, usually, through imaging tests. Despite the high prevalence and risk of complications, there is
no specific treatment approved, though a vast number of medications have been tested.
Objective::
To determine the efficacy of dipeptidyl peptidase IV inhibitors (i DPP-IV) in the treatment of NAFLD.
Methods::
We searched the electronic databases of the Cochrane Library, MEDLINE, EMBASE and LILACS, as well as
reference lists of the included studies and grey literature; 9 studies were selected for inclusion.
Results::
7 studies were used for metanalysis, for 3 outcomes. i DPP-IV showed an ALT-reducing power of MD -10.83
[95% CI 35.23 to 13.57] at 3 months and MD -9.27 [95% CI 10.92 to -7.62] at 6 months of intervention, as well as
reduction of hepatic steatosis via MRI of SMD 0.10 [95% CI 0.31 to 0.50]; the overall incidence of adverse events was
very low. The studies were considered of low and very low quality by the GRADE evaluation.
Conclusion::
Because of the poor overall quality of the studies and heterogeneity of the population analyzed, i DPP-IV did
not show efficacy on inflammatory markers or fibrosis in patients with NAFLD.
Molecular basis of the anti-diabetic properties of camel milk through profiling of its bioactive peptides on dipeptidyl peptidase IV (DPP-IV) and insulin receptor activity
